“…Similarly, we observed a reduction of serum EGFR in OSCC patients, but it was not possible to recognize any important impact on survival. Nonetheless, relevant series investigating its diagnostic value for OSCC are still limited and show inconclusive results and contradictory outcomes . These highly heterogeneous findings may be related to lower tumor bulk compared to the other neoplasms investigated (i.e., breast, lung, and ovarian cancer) and, consequently, less impact on serum concentrations of EGFR.…”